Natera/$NTRA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Ticker

$NTRA
Sector
Primary listing

Employees

4,429

Natera Metrics

BasicAdvanced
$23B
-
-$1.92
1.76
-

What the Analysts think about Natera

Analyst ratings (Buy, Hold, Sell) for Natera stock.

Bulls say / Bears say

Q2 2025 revenue rose 32.2% year-over-year to $546.6 million, driven by strong demand across its oncology, women’s health, and organ health franchises (Reuters)
Test volumes increased 12.2% year-over-year in Q2 2025, including a 50.6% surge in oncology tests, underscoring accelerating adoption of the Signatera MRD assay (Reuters)
Gross margin expanded to 63.4% in Q2 2025 from 58.8% a year ago, benefiting from cost efficiencies and incremental cash true-ups (Reuters)
Net loss widened to $100.9 million in Q2 2025 from $37.5 million a year earlier, putting pressure on EPS at ($0.74) per share (Reuters)
Operating expenses rose sharply to $457 million in Q2 2025, up 59.2% year-over-year, undermining profitability in spite of strong revenue growth (Reuters)
Natera faces a trade-secret lawsuit from Guardant Health filed in February 2025, alleging theft of confidential files and introducing legal risk and potential liabilities (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Natera Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Natera Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs